KRAS and non-small cell lung carcinoma: Adagrasib (KrazatiTM) (Figure 11) is indicated for the treatment of metastatic or KRAS G12C-mutated locally advanced non-small cell lung cancer in adults who have received at least one prior systemic therapy.